Extensive chemical library Aurora Fine Chemicals maintains a vast stock of 18.1 million compounds for R&D and drug discovery, presenting a strong upsell opportunity to customers seeking diverse screening libraries and rapid hit generation.

Advanced modeling capabilities With a Molecular Modeling Group and first-principles quantum mechanical analysis, the company can offer high-quality in silico hit and lead optimization support, appealing to clients requiring computational design and structure-based project strategies.

R&D services portfolio In addition to materials, the firm provides drug discovery services, custom synthesis, and fragment-based libraries, enabling integrated solutions for pharma and biotech teams looking to outsource synthesis and library expansion.

Global research applicability Products are used in pharmaceutical development, diagnosis, and chemical production across labs worldwide, suggesting cross-border sales potential and opportunities with universities, CROs, and small to mid-sized pharma firms.

Data and compliance edge The emphasis on precise analytical methods (GC, HPLC, NMR, MS, crystallography) and robust software models positions Aurora as a quality-focused supplier, which can be leveraged in procurement conversations emphasizing reproducibility and regulatory alignment.